Our companies most valuable asset

Currently Solid Form Solutions Ltd employs 42 staff, which comprise mainly of three teams:

  • Solid Form Screening
  • Scale-up Crystallisation and Particle Engineering
  • GMP Analytical and Physical Properties Testing

Each team brings a valuable set of skills and experience to each project allowing SFS to deliver to the highest possible standards and deliver solutions to our clients that have facilitated rapid, low risk and cost effective drug development campaigns.

SFS also has a Quality Assurance section along with other administration functions.

At the forefront of this expansion, Solid Form Solutions’ business development section is headed up by Julie Scott. Julie, a founding member of the company, spent over 15 years in the financial sector working as a Bank Manager for HBOS where she specialised in sales and marketing. Her unique approach has proved invaluable to the company and has been a catalyst to SFS’s early success. Over the past 18 months, the Business Development section have grown SFS’s client base at a remarkable rate and have contributed to retaining a large proportion of these clients for six months or more. Solid Form Solutions aim to expand their business development section in the coming months with personnel based in the US and mainland Europe.

SFS Chief Executive Officer is Dr Stephen Watt. Having gained a PhD in materials science from Heriot-Watt University, Stephen moved on to take up a post-doctoral position under Professor William Jones at the prestigious Pfizer Institute for Pharmaceutical Materials Science, Cambridge University where he published a number of papers. Dr Watt then moved onto a CRO in Cambridge before moving to the Solid Form Sciences Group at GSK. Prior to heading up SFS, Stephen has also held leading roles within other CRO’s.

In addition to Dr Stephen Watt, Dr David Pearson is the Technical Director at Solid Form Solutions. David gained his B.Sc. and Ph.D. from the University of Sheffield working under Prof. Jim Anderson on natural product total synthesis. David has a tremendously strong background in understanding the structures of molecules. After Sheffield University, David moved to Imperial College in London as a postdoctoral research associate under Prof. A. G. M. Barrett working on combinatorial chemistry and drug like molecules. Following this, David worked in medicinal chemistry at Cambridge Discovery Chemistry (later acquired by Millennium Pharmaceuticals, and then Takeda) and Inpharmatica. Subsequent to his medicinal chemistry experiences, David moved into the world of solid form research and has worked solely in the field of contract research ever since. This focus on molecules in the solid state, coupled with an understanding and experience of synthetic chemistry, DMPK, process chemistry if full leveraged into the work performed at Solid Form Solutions.

The Solid Form Solutions’ Quality Assurance section is headed up by Helen Addison. Helen has over 15 years experience in QC and QA roles and has been involved in the delivery of quality systems and controls within large scale chemical manufacturing and pharmaceutical industries, clinical laboratories, and most recently, biological, cell culture and vaccine production. As well as having an extensive knowledge of cGMP, GLP, ISO, FDA & ICH regulations, Helen is well used to dealing with a global client base and has had extensive interactions with many regulatory bodies. Having such highly qualified QA personnel at Solid Form Solutions, is key and ensures that quality is at the forefront of SFS’s current and future operations.